Volume 13, Number 7—July 2007
Research
Antiretroviral Therapy during Tuberculosis Treatment and Marked Reduction in Death Rate of HIV-Infected Patients, Thailand1
Somsak Akksilp*, Opart Karnkawinpong*, Wanpen Wattanaamornkiat*, Daranee Viriyakitja†, Patama Monkongdee‡, Walya Sitti*, Dhanida Rienthong†, Taweesap Siraprapasiri†‡, Charles D. Wells§, Jordan W. Tappero‡§, and Jay K. Varma†§
Table 1
Characteristics of HIV-infected patients with tuberculosis (TB), Ubon-ratchathani, February 2003 through January 2004
| Characteristic | Patients (N = 329), no. (%) |
|---|---|
| Female | 112 (34) |
| Median age, y (range) | 32 (0.8–68) |
| Type, location of TB | |
| Sputum smear-positive, pulmonary | 120 (36) |
| Sputum smear-negative, pulmonary | 107 (33) |
| Extrapulmonary | 102 (31) |
| Category of TB | |
| New | 307 (93) |
| Treatment after interruption, failure, default, or relapse | 11 (4) |
| Other | 11 (3) |
| HIV status known before TB diagnosis | 225 (68) |
| CD4 count (cells/mm3) | |
| <50 | 95 (29) |
| 50–99 | 39 (12) |
| 100–199 | 36 (11) |
| >200 | 25 (8) |
| Unknown | 134 (41) |
| Received co-trimoxazole during TB treatment | 225 (68) |
| Received antiretroviral therapy (ART) | |
| Before TB diagnosis | 30 (9) |
| During TB treatment | 45 (14) |
| Not prescribed ART | 254 (77) |
| Among patients receiving ART, regimen prescribed (n = 75) | |
| Stavudine/Lamivudine/Nevirapine | 38 (51) |
| Stavudine/Lamivudine/Efavirenz | 35 (47) |
| Other | 2 (2) |
| Treatment outcome | |
| Cured | 61 (19) |
| Completed | 126 (38) |
| Failure | 4 (1) |
| Default | 31 (9) |
| Transfer | 4 (1) |
| Change of diagnosis | 4 (1) |
| Died | 99 (30) |
Data from this manuscript have been presented in part at the 36th UNION World Conference on Lung Health, Paris, October 2005, and the 15th Annual International AIDS Conference, Bangkok, July 2004.
Page created: June 21, 2010
Page updated: June 21, 2010
Page reviewed: June 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.